Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
10674.17%
operating margin TTM
10763.47%
revenue TTM
2.02 Million
revenue per share TTM
0.02$
valuation ratios | |
|---|---|
| pe ratio | -1.90 |
| peg ratio | -0.20 |
| price to book ratio | 1.97 |
| price to sales ratio | -236.36 |
| enterprise value multiple | -2.41 |
| price fair value | 1.97 |
profitability ratios | |
|---|---|
| gross profit margin | 235.06% |
| operating profit margin | 10763.47% |
| pretax profit margin | 8487.82% |
| net profit margin | 10674.17% |
| return on assets | -74.99% |
| return on equity | -374.14% |
| return on capital employed | -103.75% |
liquidity ratio | |
|---|---|
| current ratio | 3.61 |
| quick ratio | 3.61 |
| cash ratio | 3.09 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 546.50 |
| cash conversion cycle | -546.50 |
| receivables turnover | 0.00 |
| payables turnover | 0.67 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.03 |
| interest coverage | -416.70 |
| cash flow to debt ratio | -32.80 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.30 |
| cash per share | 0.36 |
| operating cash flow per share | -0.30 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -32.80 |
| short term coverage ratios | -48.83 |
| capital expenditure coverage ratio | -529.32 |
Frequently Asked Questions
When was the last time Unicycive Therapeutics, Inc. (NASDAQ:UNCY) reported earnings?
Unicycive Therapeutics, Inc. (UNCY) published its most recent earnings results on 13-11-2024.
What is Unicycive Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Unicycive Therapeutics, Inc. (NASDAQ:UNCY)'s trailing twelve months ROE is -374.14%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Unicycive Therapeutics, Inc. (UNCY) currently has a ROA of -74.99%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did UNCY's net profit margin stand at?
UNCY reported a profit margin of 10674.17% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is UNCY's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.61 in the most recent quarter. The quick ratio stood at 3.61, with a Debt/Eq ratio of 0.03.